The Week In...Pharma (11-15/11)
  • Posted on: 15/11/2019
  • Category: Industry

The Week In...Pharma (11-15/11)

NICE recommends Bayer’s MS treatment, complementary cancer therapies ‘do more harm than good’, and could greater collaboration accelerate much-needed treatments for children with rare diseases? 

Interested in Star’s innovative outsourcing and resourcing solutions? 

Contact Operations Director, Mark Ward, on 07872 105 540 or email mark.ward@starmedical.co.uk. 

On the hunt for a new role, or just curious? 

Visit our candidate page, submit your CV to candidates@starmedical.co.uk, or give our offices a ring! 

Joined up thinking and innovation will boost drug development in rare diseases

Fresh thinking and greater collaboration at the European level could accelerate the much-needed development of treatments and cures for children with rare diseases.

Complementary cancer therapies 'do more harm than good'

Cancer patients should tell their doctors if they are taking herbal products because some of the ingredients could stop their treatment working, a cancer conference has heard.

NICE ‘OK’ for Sativex in MS

The National Institute for Health and Care Excellence (NICE) has recommended Bayer’s Sativex (delta-9 tetrahydrocannabinol (THC) cannabidiol (CBD)), for spasticity in people with multiple sclerosis (MS).

Merck builds in CNS diseases with $576m Calporta buy

Merck & Co has had mixed fortunes in neurological diseases of late, but remains committed to the category and has just bolstered its early-stage pipeline with a $576 million agreement to acquire Calporta Therapeutics.

Daiichi Sankyo announces results of Phase 3 CLEAR Wisdom trial for bempedoic acid

Daiichi Sankyo Europe GmbH has announced the publication of results from the Phase 3 CLEAR Wisdom trial in the Journal of the American Medical Association (JAMA).

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.